Antipsychotic Discontinuation in Alzheimer's Disease

Trial Profile

Antipsychotic Discontinuation in Alzheimer's Disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Risperidone (Primary)
  • Indications Aggression; Agitation; Alzheimer's disease; Psychotic disorders
  • Focus Therapeutic Use
  • Acronyms ADAD
  • Most Recent Events

    • 18 Oct 2012 Primary endpoint 'Time-to-relapse' has been met.
    • 18 Oct 2012 Results published in the New England Journal of Medicine.
    • 19 Jul 2012 Results presented at the 2012 International Conference on Alzheimer's Disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top